Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Alembic Pharmaceuticals
Mid Cap•14,858 Employees•IPO 2011
Current Price
₹677.95
-25.35 (-3.6%)Updated
Today's Range
675
₹677.95
704.95
52 Week Range
52W Low₹682.00
52W High₹1107.90
₹677.95
Downside-0.59%
Upside63.42%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹15,261.16 Cr
Market Cap
Total market value of companyP/E Ratio
24.26
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.33
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹32.06
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.50%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
13.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
8.65%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-7.51%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
7.69%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
9.54%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
14.60%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.24
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹264.09
Book Value
Net asset value per shareDividend Yield
1.42%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
69.70%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Robust promoter holding (69.7%) indicates strong management confidence and stability.
- •Healthy Return on Equity (11.4%) demonstrates efficient utilization of shareholder capital.
Weaknesses
5 points- •P/E ratio (29.90) is higher than peers, suggesting potential relative overvaluation.
- •Quarterly profit growth (14.60%) lags peers, indicating decelerating earnings momentum.
Opportunities
5 points- •Pharmaceutical sector poised for robust growth from global healthcare demand.
- •Smaller market capitalization offers significant potential for market share expansion.
Threats
5 points- •Intense competition from larger players could pressure pricing and market share.
- •Stringent regulatory changes, including drug pricing controls, impact operational flexibility.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
- | 13 Feb 2025 | 14 Feb 2025 | 7.48 L | 24,773 | ₹842.08 | BUY |
Chirayu Ramanbhai Amin HUF | 14 Feb 2025 | 17 Feb 2025 | 7.58 L | 10,000 | ₹812.9 | BUY |
Chirayu Ramanbhai Amin HUF | 20 Feb 2025 | 21 Feb 2025 | 7.59 L | 959 | ₹811.92 | BUY |
Chirayu Ramanbhai Amin HUF | 21 Feb 2025 | 24 Feb 2025 | 7.63 L | 4,247 | ₹806.14 | BUY |
Chirayu Ramanbhai Amin HUF | 25 Feb 2025 | 26 Feb 2025 | 7.71 L | 7,426 | ₹797.91 | BUY |
Chirayu Ramanbhai Amin HUF | 27 Feb 2025 | 28 Feb 2025 | 8.21 L | 50,000 | ₹778.25 | BUY |
Chirayu Ramanbhai Amin HUF | 17 Mar 2025 | 18 Mar 2025 | 8.26 L | 5,832 | ₹826.25 | BUY |
Chirayu Ramanbhai Amin HUF | 18 Mar 2025 | 20 Mar 2025 | 8.28 L | 1,500 | ₹832.52 | BUY |
Chirayu Ramanbhai Amin HUF | 20 Mar 2025 | 21 Mar 2025 | 8.30 L | 2,000 | ₹834.46 | BUY |
NIRAYU LIMITED | 21 Mar 2025 | 24 Mar 2025 | 7.00 Cr | 7,600 | ₹866.74 | BUY |
NIRAYU LIMITED | 28 Mar 2025 | 28 Mar 2025 | 7.01 Cr | 12,665 | ₹905.13 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹756.83 | +₹78.88 | +11.64% |
| R3 | ₹726.88 | +₹48.93 | +7.22% |
| R2 | ₹715.92 | +₹37.97 | +5.60% |
| R1 | ₹696.93 | +₹18.98 | +2.80% |
| PIVOT | ₹685.97 | 8.02 | 1.18% |
| CURRENT | ₹677.95 | - | - |
| S1 | ₹607.08 | -₹70.87 | -10.45% |
| S2 | ₹637.03 | -₹40.92 | -6.04% |
| S3 | ₹656.02 | -₹21.93 | -3.24% |
| S4 | ₹666.98 | -₹10.97 | -1.62% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-21.2% vs avg
0.45L
(13 Mar 2026)Delivery %+9.9% vs avg
52.0%
(13 Mar 2026)Avg Volume (20D)20-day average
0.58L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
42.1%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Astrazeneca Pharma India Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Limited (APLLTD) is a fully integrated pharmaceutical company with a global reach. Its operations span the entire pharmaceutical value chain, from the initial research and development of new drugs to the final manufacturing, marketing, and sales of finished pharmaceutical products. This comprehensive approach allows them to exert greater control over quality and efficiency across all stages of production and distribution.
APLLTD's product portfolio is extensive and covers a wide range of therapeutic areas. This diversity is a key strength, allowing the company to cater to a broad spectrum of patient needs and market demands. Their offerings include products for cardiology, orthopaedics, diabetes management, ophthalmology, gynecology, nephrology, gastroenterology, urology, dermatology, infectious diseases, respiratory ailments (cold and cough), and even animal health. This diversification reduces reliance on any single therapeutic area and mitigates risk.
The company manufactures a variety of dosage forms, further showcasing its production capabilities. These include oral solid formulations (tablets and capsules), oncology-focused oral solids and injectables, general injectable medications, ophthalmic products, dermatological preparations, and oral suspensions. The production of active pharmaceutical ingredients (APIs) internally also grants APLLTD greater control over the supply chain and reduces dependence on external suppliers.
A significant aspect of APLLTD's business is its export operations. The company actively sells its products internationally, expanding its market reach and diversifying its revenue streams. This global presence provides resilience against fluctuations in any single national market and contributes significantly to the company's overall financial performance. The company's long history, dating back to 1907, demonstrates a sustained commitment to the pharmaceutical industry and suggests a strong foundation of experience and expertise.
In summary, Alembic Pharmaceuticals Limited operates as a comprehensive pharmaceutical company, engaged in the entire life cycle of pharmaceutical products, from research to global distribution. Its diversified product portfolio, wide range of dosage forms, and international reach contribute to its established position within the pharmaceutical market. The company's long history and vertical integration provide a solid base for continued growth and success.
COMPANY FACTS - APLLTD
Registered Address
Alembic Road
Vadodara
GUJARAT
IN
Tel: 912656637000
Website:https://alembicpharmaceuticals.com/
Investor Relations:http://alembicpharmaceuticals.com/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 14,858
IPO Date: 17/09/2011
MANAGEMENT - APLLTD
Mr. Chirayu Amin
Executive Chairman of the Board, Chief Executive Officer
Mr. G. Krishnan
Chief Financial Officer
Ms. Manisha Saraf
Compliance Officer, Company Secretary
Shri. Pranav Amin
Managing Director, Executive Director
Mr. Shaunak Amin
Managing Director, Executive Director
Mr. Raj Baheti
Executive Director
Mr. Ashok Barat
Non-Executive Independent Director
Mr. Jai Diwanji
Non-Executive Independent Director
Ms. Geeta Goradia
Non-Executive Independent Director
Mr. Manish Kejriwal
Non-Executive Independent Director
Investor Questions Answered
Alembic Pharmaceuticals Ltd (APLLTD) Stock FAQs
Get answers to the most common questions about Alembic Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Alembic Pharmaceuticals Ltd (APLLTD) is ₹677.95. Today, the stock has declined by ₹25.35 (3.60%), trading in a range of ₹675 to ₹704.95. The stock opened at ₹703.3 with a trading volume of 45,309 shares.
Alembic Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,261.16 crores, P/E ratio of 24.26, ROE of 6.50%, and ROCE of 13.00%. The dividend yield stands at 1.42%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Alembic Pharmaceuticals Ltd (APLLTD) is ₹1,107.9, while the 52-week low is ₹682. Currently trading at ₹677.95, the stock is -1.0% away from its 52-week low and 38.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Alembic Pharmaceuticals Ltd stock at ₹677.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 24.26 and P/B ratio of N/A. Today's performance shows a loss of 3.60%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Alembic Pharmaceuticals Ltd offers a dividend yield of 1.42%, which means for every ₹100 invested at the current price of ₹677.95, you can expect to receive approximately ₹1.42 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Alembic Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 24.26, P/B Ratio: N/A, ROE: 6.50%, ROCE: 13.00%, Dividend Yield: 1.42%, EPS: ₹32.06, Book Value: ₹264.09, Debt-to-Equity: 0.24, and Current Ratio: N/A. The company's market cap stands at ₹15,261.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Alembic Pharmaceuticals Ltd stock opened at ₹703.3 and is currently trading at ₹677.95, showing a decline of ₹25.35 (3.60%). The intraday high is ₹704.95 and low is ₹675. The trading volume stands at 45,309 shares, indicating moderate market participation today.
Alembic Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 24.26, which means investors are willing to pay ₹24.26 for every ₹1 of earnings. With an EPS of ₹32.06, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Alembic Pharmaceuticals Ltd has a market capitalization of ₹15,261.16 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹677.95) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Alembic Pharmaceuticals Ltd has a book value of ₹264.09 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹677.95, which is 156.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Alembic Pharmaceuticals Ltd has a Return on Equity (ROE) of 6.50% and Return on Capital Employed (ROCE) of 13.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Alembic Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Alembic Pharmaceuticals Ltd has a debt-to-equity ratio of 0.24, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Alembic Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹32.06, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹677.95 and P/E ratio of 24.26, investors are paying 24.26 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Alembic Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Alembic Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Alembic Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (24.26), ROE (6.50%), debt-to-equity (0.24), and growth rates. 2) Technical Analysis - Check 52-week range (₹682.00 - ₹1107.90), moving averages, and chart patterns. 3) Valuation - Compare current price (₹677.95) with book value (₹264.09) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Alembic Pharmaceuticals Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹677.95 is 33798x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Alembic Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹682.00 - ₹1107.90). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.24 indicates leverage. 4) Liquidity Risk - Based on trading volume of 45,309 shares. 5) Valuation Risk - P/E of 24.26 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Alembic Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 24.26, ROE of 6.50%, market cap of ₹15,261.16 crores, and dividend yield of 1.42%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.24), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Alembic Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹677.95, with a 52-week range of ₹682.00 to ₹1107.90. Based on fundamentals like P/E (24.26), ROE (6.50%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Alembic Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹677.95. 2) Fundamental Deterioration - Declining ROE (currently 6.50%), increasing debt (D/E: 0.24), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Alembic Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.42%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu